Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a ...

Trials should assess overall survival to evaluate potential harm, with crossover limited to avoid confounding treatment ...

The study reported a higher incidence of serious TEAEs and TEAEs leading to death in the xevinapant group, indicating poor ...

FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...

The primary end point of the dose-expansion portion was safety of NBTXR3 at the recommended dosage, 1 which was established ...

Dr Colette Shen discusses the innovative Study 1100, exploring NBTXR3's safety and efficacy in treating recurrent head and ...

Physician shortages are causing burnout, turnover, and patient access issues, with many considering early retirement or ...

SpaceOAR Hydrogel is a polyethylene glycol–based hydrogel designed to create space between the prostate and rectum to reduce ...

With the 2025 European Society of Medical Oncology (ESMO) Congress kicking off on Friday, October 17, in Berlin, Germany, Targeted Oncology is bringing you background on the most exciting abstracts ...

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

The FDA has granted breakthrough therapy designation (BTD) to the investigational B-cell lymphoma 2 (BCL2) inhibitor ...

Discover how rectal spacers revolutionize prostate cancer treatment by reducing side effects and enhancing radiation dose ...